Invivyd Announces That The New England Journal Of Medicine Has Published A Peer-reviewed Letter To The Editor Describing The Pemgarda (Pemivibart) Immunobridging Emergency Use Authorization Pathway, As Well As An Updated Correlate Of Protection Curve...

Invivyd 宣佈《新英格蘭醫學雜誌》已發表了一封經過同行評審的編輯信，描述了 Pemgarda（Pemivibart）免疫橋接緊急使用授權途徑，以及更新的保護相關曲線......

Benzinga · 11/14 20:07

Invivyd Announces That The New England Journal Of Medicine Has Published A Peer-reviewed Letter To The Editor Describing The Pemgarda (Pemivibart) Immunobridging Emergency Use Authorization Pathway, As Well As An Updated Correlate Of Protection Curve For Prevention Of Symptomatic Covid-19 Via Recombinant Monoclonal Antibodies Such As Pemivibart

Invivyd 宣佈《新英格蘭醫學雜誌》已發表了一封經過同行評審的編輯信，描述了 Pemgarda（Pemivibart）免疫橋接緊急使用授權途徑，以及更新的保護相關曲線，旨在通過重組單克隆抗體如 Pemivibart 預防有症狀的 Covid-19

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。